Kymera Therapeutics (KYMR) Equity Average (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Equity Average data on file, last reported at $1.6 billion in Q1 2026.

• Equity Average for Q1 2026 came in at $1.6 billion, up 92.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 92.33% YoY), and the FY2025 annual result was $1.2 billion, up 96.27% from the prior year.
• Equity Average advanced to $1.6 billion in Q1 2026 per KYMR's latest filing, from $1.3 billion in the prior quarter.
• Over five years, Equity Average peaked at $1.6 billion in Q1 2026 and troughed at $395.3 million in Q4 2023.
• A 5-year average of $701.5 million and a median of $553.1 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2023 and 2024: Equity Average decreased 21.19% in 2023, then surged 118.66% in 2024.
• A 5-year view of Equity Average shows it stood at $501.5 million in 2022, then fell by 21.19% to $395.3 million in 2023, then surged by 118.66% to $864.3 million in 2024, then soared by 46.13% to $1.3 billion in 2025, then advanced by 23.49% to $1.6 billion in 2026.
• Business Quant data shows KYMR's Equity Average at $1.6 billion in Q1 2026, $1.3 billion in Q4 2025, and $958.9 million in Q3 2025.